211 related articles for article (PubMed ID: 35372049)
1. Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
Li Y; Nie Y; Guo H; Guo H; Ha C; Li Y
Front Oncol; 2022; 12():847085. PubMed ID: 35372049
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
Liu J; Liu Y; Yang C; Liu J; Hao J
Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
[TBL] [Abstract][Full Text] [Related]
4. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
5. Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer.
Jiang H; Awuti G; Guo X
ACS Omega; 2023 Sep; 8(36):33017-33031. PubMed ID: 37720747
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics evaluation of a novel angiogenesis related genes-based signature for predicting prognosis and therapeutic efficacy in patients with gastric cancer.
Ma N; Li J; Lv L; Li C; Li K; Wang B
Am J Transl Res; 2022; 14(7):4532-4548. PubMed ID: 35958480
[TBL] [Abstract][Full Text] [Related]
7. Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
Li Y; Zhang X; Gao Y; Shang C; Yu B; Wang T; Su J; Huang C; Wu Y; Guo H; Ha C
Front Oncol; 2020; 10():625866. PubMed ID: 33747898
[TBL] [Abstract][Full Text] [Related]
8. A Novel Platinum Resistance-Related Immune Gene Signature for Overall Survival Prediction in Patients with Ovarian Cancer.
Zhou C; Ma J; Luo W; Hu J; Chen J; Liang S; He S
Biochem Genet; 2024 Feb; 62(1):112-124. PubMed ID: 37270714
[TBL] [Abstract][Full Text] [Related]
9. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.
Chen S; Wu Y; Wang S; Wu J; Wu X; Zheng Z
J Ovarian Res; 2022 Mar; 15(1):39. PubMed ID: 35361267
[TBL] [Abstract][Full Text] [Related]
10. Identifying Explainable Machine Learning Models and a Novel SFRP2
Yang Z; Zhou D; Huang J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069266
[TBL] [Abstract][Full Text] [Related]
11. Immune-related gene signature to predict TACE refractoriness in patients with hepatocellular carcinoma based on artificial neural network.
Xu Q; Wang C; Yin G
Front Genet; 2022; 13():993509. PubMed ID: 36685822
[No Abstract] [Full Text] [Related]
12. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
13. An amino acid metabolism-based seventeen-gene signature correlates with the clinical outcome and immune features in pancreatic cancer.
Hao J; Zhou C; Wang Z; Ma Z; Wu Z; Lv Y; Wu R
Front Genet; 2023; 14():1084275. PubMed ID: 37333498
[No Abstract] [Full Text] [Related]
14. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.
Duan Y; Xu X
Front Endocrinol (Lausanne); 2023; 14():1193622. PubMed ID: 37383389
[TBL] [Abstract][Full Text] [Related]
15. A Platinum Resistance-Related lncRNA Signature for Risk Classification and Prognosis Prediction in Patients with Serous Ovarian Cancer.
Zhu Y; Chen J; Zhou L; Zhang L; Liu Y; Zhuang Y; Peng L; Huang YT
J Oncol; 2022; 2022():7625138. PubMed ID: 37223641
[TBL] [Abstract][Full Text] [Related]
16. A gene signature driven by abnormally methylated DEGs was developed for TP53 wild-type ovarian cancer samples by integrative omics analysis of DNA methylation and gene expression data.
Zhou Z; Jin H; Xu J
Ann Transl Med; 2023 Jan; 11(1):20. PubMed ID: 36760264
[TBL] [Abstract][Full Text] [Related]
17. A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score.
Yang F; Wei W; Li G; Lan Q; Liu X; Gao L; Zhang C; Fan J; Li J
Front Genet; 2023; 14():1240068. PubMed ID: 37732324
[No Abstract] [Full Text] [Related]
18. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
[TBL] [Abstract][Full Text] [Related]
20. Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in ovarian cancer treatment.
Yi X; Liu Y; Zhou B; Xiang W; Deng A; Fu Y; Zhao Y; Ouyang Q; Liu Y; Sun Z; Zhang K; Li X; Zeng F; Zhou H; Chen BT
Biomed Pharmacother; 2021 Jan; 133():111013. PubMed ID: 33227705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
